Type 2B vWD: The varied clinical manifestations in two kindreds

Haemophilia

Volumn 9, Issue 1, 2003, Pages 137-144

  Mathew, P ^a   Greist, A ^b   Maahs, J A ^b   Lichtenberg, E C ^b   Shapiro, A D ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

Author keywords

Humate P ; Thrombocytopenia; Type 2B von Willebrand's disease

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN III; ARGININE; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DINUCLEOTIDE; GLYCOPROTEIN; IMMUNOGLOBULIN; PHOSPHOLIPID ANTIBODY; POLYMER; PROTEIN C; PROTEIN S; RISTOCETIN; STEROID; TRANEXAMIC ACID; TRYPTOPHAN; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; ELECTIVE SURGERY; EPISTAXIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENETIC DISORDER; HUMAN; IN VIVO STUDY; LABORATORY DIAGNOSIS; MALE; MENORRHAGIA; MISSENSE MUTATION; MOLECULAR WEIGHT; NUCLEIC ACID BASE SUBSTITUTION; PREGNANCY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; RISK ASSESSMENT; STRESS; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

EID: 0037276212     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00712.x     Document Type: Article

References (22)

1. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
2. Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemost 1992; 67: 594-99.
3. Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand disease. N Engl J Med 1980; 302: 1047-51.
4. White GC II, Montgomery RR. Clinical aspects of and therapy for von Willebrand disease. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice 3rd edn. New York, NY: Churchill Livingstone, 2000: 1946-58.
5. Schneppenheim R, Thomas KB, Sutor AH. Willebrand disease in childhood. Semin Thromb Hemost 1995; 21: 261-75.
6. Werner EJ. von Willebrand disease in children and adolescents. Pediatr Clin North Am 1996; 43: 683-707.
7. Ginsberg D, Bowie EJ. Molecular genetics of von Willebrand disease. Blood 1992; 79: 2507-19.
8. Ginsberg D, Sadler JE. Von Willebrand disease: a data base of point mutations, insertions, and deletions. Thromb Haemost 1993; 69: 177-84.
9. Nichols WC, Ginsberg D. Willebrand disease. Medicine 1997; 76: 1-20.
10. Federici AB, Mannucci PM. Advances in the genetics and treatment of von Willebrand disease. Curr Opin Pediatr 2002; 14: 23-33.
11. Ginsberg D, Wagner DD. Structure, biology, and genetics of von Willebrand factor. In: Hoffman R, Benz EJ, Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice. 3rd edn. New York, NY: Churchill Livingstone; 2000: 1937-45.
12. Rick ME. Diagnosis and management of von Willebrand's syndrome. Med Clin North Am 1994; 78: 609-23.
13. Cattaneo M, Federici AB, Mannucci PM. Diagnosis and management of von Willebrand's disease. Int J Pediatr Hematol/Oncol 1994; 1: 499-508.
14. Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorin E. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type 2B von Willebrand's disease. N Engl J Med 1983; 309: 816-21.
15. Facey DA, Favaloro EJ, Koutts J, Berndt MC, Hertzberg MS. Identification and characterization of a novel mutation in von Willebrand factor causing type 2B von Willebrand's disease. Br J Haematol 1999; 105: 538-41.
16. Rick ME, Williams SB, Sacher RA et al. Thrombocytopenia associated with pregnancy in a patient with type II B vWD. Blood 1987; 69: 786-89.
17. Meyer D, Fressinaud E, Gaucher C et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. Thromb Haemost 1997; 78: 451-56.
18. Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand disease with a VHP vWF concentrate: the French experience. Haemophilia 1998; 4: 48-52.
19. Mauz-Korholz C, Budde U, Kruck H, Korholz D, Gobel U. Management of severe chronic thrombocytopenia in von Willebrand disease type 2B. Arch Dis Child 1998; 78: 257-60.
20. de Romeuf C, Hilbert L, Mazurier C. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations. Thromb haemost 1998; 79: 211-16.
21. Casonato A, Steffan A, Pontara E et al. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Thromb Haemost 1999; 81: 224-28.
22. Lankhof H, Damas C, Schiphorst ME et al. Functional studies on platelet adhesion with recombinant von Willebrand factor type 2B mutants R543Q and R543W under conditions of flow. Blood 1997; 89: 2766-2772.